Pfizer (PFE) Treasury Shares (2009 - 2026)
Pfizer (PFE) posted quarterly Treasury Shares of $115.2 billion for Q1 2026, little changed year-over-year from $115.0 billion in Q1 2025, and little changed quarter-over-quarter from $115.0 billion in Q4 2025.
Pfizer (PFE) Treasury Shares (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Treasury Shares for 18 consecutive years, with $115.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Treasury Shares changed 0.16% year-over-year to $115.2 billion; the TTM figure through Mar 2026 stood at $115.2 billion (changed 0.16% YoY), while the FY2025 annual figure was $115.0 billion, changed 0.22% from the prior year.
- Treasury Shares held at $115.2 billion in Q1 2026 per PFE's latest filing, from $115.0 billion in the prior quarter.
- Across five years, Treasury Shares topped out at $3.9 billion in Q1 2026 and bottomed at $3.9 billion in Q2 2022.
- Historically, Treasury Shares has averaged $3.9 billion across 5 years, with a median of $3.9 billion in 2024.
- Annual changes were most pronounced in 2023 — Treasury Shares jumped 5624.1% — and 2026, when it grew 0.16%.
- Pfizer's Treasury Shares stood at $114.0 billion in 2022, then advanced by 0.45% to $114.5 billion in 2023, then advanced by 0.24% to $114.8 billion in 2024, then increased by 0.22% to $115.0 billion in 2025, then grew by 0.15% to $115.2 billion in 2026.
- Business Quant data shows PFE's Treasury Shares at $115.2 billion in Q1 2026, $115.0 billion in Q4 2025, and $115.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.81 Bn | 632.06 Bn | 17.26 Bn | 75.86 Bn |
| 2 | AbbVie | 470.36 Bn | 463.79 Bn | 12.70 Bn | 77.11 Mn |
| 3 | Merck | 375.71 Bn | 368.57 Bn | 12.21 Bn | 1.11 Bn |
| 4 | Novartis Ag | 303.50 Bn | 295.81 Bn | 11.24 Bn | 49.00 Mn |
| 5 | Astrazeneca | 257.38 Bn | 252.48 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.44 Bn | 222.45 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.93 Bn | 178.75 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.38 Bn | 147.68 Bn | 10.94 Bn | 115.19 Bn |
| 9 | Gsk | 106.17 Bn | 102.00 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.13 Bn | 47.75 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 3.94 Bn |
| Jun 28, 2026 | 115.19 Bn |
| Jun 28, 2026 | 115.19 Bn |
| Jun 28, 2026 | 3.94 Bn |
| Mar 29, 2026 | 3.94 Bn |
| Mar 29, 2026 | 3.94 Bn |
| Mar 29, 2026 | 115.19 Bn |
| Mar 29, 2026 | 115.19 Bn |
| Dec 31, 2025 | 3.94 Bn |
| Dec 31, 2025 | 115.02 Bn |
| Dec 31, 2025 | 115.02 Bn |
| Dec 31, 2025 | 3.94 Bn |
| Sep 28, 2025 | 115.01 Bn |
| Sep 28, 2025 | 3.94 Bn |
| Sep 28, 2025 | 3.94 Bn |
| Sep 28, 2025 | 115.01 Bn |
| Jun 29, 2025 | 3.94 Bn |
| Jun 29, 2025 | 115.01 Bn |
| Jun 29, 2025 | 115.01 Bn |
| Jun 29, 2025 | 3.94 Bn |